SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Abamectin Liquid Formulation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Abamectin Liquid Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Substance/Mixture : Veterinary product

1.3 Details of the supplier of the safety data sheet
   Company : MSD
   Shotton Lane
   NE23 3JU Cramlington NU - Great Britain
   Telephone : 44 1 670 59 30 00
   Telefax : 908-735-1496
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

   Classification (REGULATION (EC) No 1272/2008)
   Acute toxicity, Category 4 : H332: Harmful if inhaled.
   Specific target organ toxicity - repeated exposure, Category 2 : H373: May cause damage to organs through prolonged or repeated exposure.
   Short-term (acute) aquatic hazard, Category 1 : H400: Very toxic to aquatic life.
   Long-term (chronic) aquatic hazard, Category 1 : H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

   Labelling (REGULATION (EC) No 1272/2008)
   Hazard pictograms : 
   Signal word : Warning
   Hazard statements : H332 Harmful if inhaled.
   H373 May cause damage to organs through prolonged or repeated exposure.
Abamectin Liquid Formulation

Hazardous components which must be listed on the label:
Abamectin (combination of avermectin B1a and avermectin B1b)

2.3 Other hazards
None known.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abamectin (combination of avermectin B1a and avermectin B1b)</td>
<td>71751-41-2 606-143-00-0</td>
<td>Acute Tox. 2; H300 Acute Tox. 1; H330 Acute Tox. 3; H311 Repr. 2; H361fd STOT RE 1; H372 Aquatic Acute 1; H400 Aquatic Chronic 1; H410</td>
<td>&gt;= 1 - &lt; 2.5</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures
General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled: If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed
Risks: Harmful if inhaled. May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed
Treatment: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media
Suitable extinguishing media: Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical

Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture
Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-: Carbon oxides
Abamectin Liquid Formulation

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

6.2 Environmental precautions

Environmental precautions : Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Abamectin Liquid Formulation

Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Do not breathe vapours or spray mist.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Keep container tightly closed.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers:
- Keep in properly labelled containers. Keep tightly closed.
- Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.

Advice on common storage:
- Do not store with the following product types:
  - Strong oxidizing agents
  - Organic peroxides
  - Explosives
  - Gases

7.3 Specific end use(s)

Specific use(s):
- No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abamectin (combination of avermectin B1a and avermectin B1b)</td>
<td>71751-41-2</td>
<td>TWA</td>
<td>30 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>300 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>
Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerides, mixed decanoyl and octanoyl</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>177.79 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>25.21 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>43.84 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>12.61 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>12.61 mg/kg bw/day</td>
</tr>
</tbody>
</table>

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerides, mixed decanoyl and octanoyl</td>
<td>Oral (Secondary Poisoning)</td>
<td>0.03 mg/kg food</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Combined particulates and organic vapour type (A-P)
SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

- **Appearance**: liquid
- **Colour**: light yellow
- **Odour**: characteristic
- **Odour Threshold**: No data available
- **pH**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling range**: No data available
- **Flash point**: No data available
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: Not applicable
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
- **Vapour pressure**: No data available
- **Relative vapour density**: No data available
- **Relative density**: No data available
- **Density**: 0.90 - 0.94 g/cm³
- **Solubility(ies)**
  - **Water solubility**: insoluble
  - **Partition coefficient: n-octanol/water**: Not applicable
  - **Auto-ignition temperature**: No data available
  - **Decomposition temperature**: No data available
- **Viscosity**
  - **Viscosity, kinematic**: No data available
- **Explosive properties**: Not explosive
- **Oxidizing properties**: The substance or mixture is not classified as oxidizing.

9.2 Other information

- **Flammability (liquids)**: No data available
Abamectin Liquid Formulation

SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: None known.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Harmful if inhaled.

Product:
- Acute oral toxicity: Acute toxicity estimate: > 2,000 mg/kg
  Method: Calculation method
- Acute inhalation toxicity: Acute toxicity estimate: 2.3 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
  Method: Calculation method
- Acute dermal toxicity: Acute toxicity estimate: > 2,000 mg/kg
  Method: Calculation method

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Acute oral toxicity: LD50 (Rat): 24 mg/kg
LD50 (Mouse): 10 mg/kg
LDLo (Monkey): 24 mg/kg
Symptoms: Dilatation of the pupil

Acute inhalation toxicity: LC50 (Rat): 0.023 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity: LD50 (Rat): 330 mg/kg
LD50 (Rabbit): 2,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Species: Rabbit
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Test Type: Maximisation Test
Exposure routes: Skin contact
Result: Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.
Components:

**Abamectin (combination of avermectin B1a and avermectin B1b):**

Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

Genotoxicity in vivo: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

**Abamectin (combination of avermectin B1a and avermectin B1b):**

Species: Rat
Application Route: Oral
Exposure time: 105 weeks
Result: negative

Species: Mouse
Application Route: Oral
Exposure time: 93 weeks
Result: negative

Reproductive toxicity
Not classified based on available information.

Components:

**Abamectin (combination of avermectin B1a and avermectin B1b):**

Effects on fertility: Test Type: Fertility
Species: Rat, male
Application Route: Oral
Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: NOAEL: 0.12 mg/kg body weight
Result: Fetotoxicity
Effects on foetal development:

<table>
<thead>
<tr>
<th>Test Type</th>
<th>Species</th>
<th>Application Route</th>
<th>General Toxicity Maternal</th>
<th>Developmental Toxicity</th>
<th>Result</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Embryo-foetal development</td>
<td>Mouse</td>
<td>Oral</td>
<td>NOAEL: 0.05 mg/kg body weight</td>
<td>NOAEL: 0.2 mg/kg body weight</td>
<td>Cleft palate</td>
<td>Adverse developmental effects were observed</td>
</tr>
<tr>
<td>Embryo-foetal development</td>
<td>Rabbit</td>
<td>Oral</td>
<td>LOAEL: 2 mg/kg body weight</td>
<td></td>
<td>Cleft palate, Teratogenic effects, Reduced embryonic survival</td>
<td>Adverse developmental effects were observed</td>
</tr>
<tr>
<td>Development</td>
<td>Rat</td>
<td>Oral</td>
<td>LOAEL: 1.6 mg/kg body weight</td>
<td></td>
<td>Teratogenic effects</td>
<td></td>
</tr>
</tbody>
</table>

Remarks:
Adverse developmental effects were observed.

Reproductive toxicity - Assessment:
Some evidence of adverse effects on sexual function and fertility, based on animal experiments. Some evidence of adverse effects on development, based on animal experiments.

**STOT - single exposure**
Not classified based on available information.

**STOT - repeated exposure**
May cause damage to organs through prolonged or repeated exposure.

**Components:**

**Abamectin (combination of avermectin B1a and avermectin B1b):**

- **Exposure routes**: Ingestion
- **Target Organs**: Central nervous system
- **Assessment**: Causes damage to organs through prolonged or repeated exposure.

**Repeated dose toxicity**

**Components:**

**Abamectin (combination of avermectin B1a and avermectin B1b):**

- **Species**: Rat
- **NOAEL**: 1.5 mg/kg
- **Application Route**: Oral
- **Exposure time**: 24 Months
- **Target Organs**: Central nervous system
- **Symptoms**: Tremors, ataxia
- **Species**: Mouse
### NOAEL
- **Application Route**: Oral
- **Exposure time**: 24 Months
- **Target Organs**: Central nervous system
- **Symptoms**: Tremors, ataxia

**Species**: Dog
- **NOAEL**: 0.25 mg/kg
- **LOAEL**: 0.5 mg/kg
- **Application Route**: Oral
- **Exposure time**: 53 Weeks
- **Target Organs**: Central nervous system
- **Symptoms**: Tremors, weight loss
- **Remarks**: mortality observed

**Species**: Monkey
- **NOAEL**: 1.0 mg/kg
- **Application Route**: Oral
- **Exposure time**: 14 Weeks
- **Target Organs**: Central nervous system

### Aspiration toxicity
Not classified based on available information.

### Experience with human exposure

**Components**:
**Abamectin (combination of avermectin B1a and avermectin B1b):**

**Ingestion**: Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing

### SECTION 12: Ecological information

#### 12.1 Toxicity

**Components**:

**Abamectin (combination of avermectin B1a and avermectin B1b):**

**Toxicity to fish**
- **LC50** (*Oncorhynchus mykiss* (rainbow trout)): 3.2 µg/l
  - Exposure time: 96 h
- **LC50** (*Lepomis macrochirus* (Bluegill sunfish)): 9.6 µg/l
  - Exposure time: 96 h
- **LC50** (*Ictalurus punctatus* (channel catfish)): 24 µg/l
  - Exposure time: 96 h
- **LC50** (*Cyprinus carpio* (Carp)): 42 µg/l
  - Exposure time: 96 h
- **LC50** (*Cyprinodon variegatus* (sheepshead minnow)): 15 µg/l
  - Exposure time: 96 h
Abamectin Liquid Formulation

Toxicity to daphnia and other aquatic invertebrates:
- EC50 (Americamysis): 0.022 µg/l
  Exposure time: 96 h
- EC50 (Daphnia magna (Water flea)): 0.34 µg/l
  Exposure time: 48 h

Toxicity to algae/aquatic plants:
- EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
  Exposure time: 72 h

M-Factor (Acute aquatic toxicity):
- 10,000

Toxicity to microorganisms:
- EC50: > 1,000 mg/l
  Exposure time: 3 h
  Test Type: Respiration inhibition

Toxicity to fish (Chronic toxicity):
- NOEC: 0.52 µg/l
  Exposure time: 32 d
  Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity):
- NOEC: 0.03 µg/l
  Exposure time: 21 d
  Species: Daphnia magna (Water flea)
- NOEC: 0.0035 µg/l
  Exposure time: 28 d
  Species: Mysidopsis bahia (opossum shrimp)

M-Factor (Chronic aquatic toxicity):
- 10,000

12.2 Persistence and degradability

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Stability in water:
- Hydrolysis: 50 %(< 12 h)

12.3 Bioaccumulative potential

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Bioaccumulation:
- Bioconcentration factor (BCF): 52
Partition coefficient: n-octanol/water:
- log Pow: 4

12.4 Mobility in soil

Components:
Abamectin (combination of avermectin B1a and avermectin B1b):
Distribution among environments:
- log Koc: > 3.6
mental compartments

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
ADN: UN 3082
ADR: UN 3082
RID: UN 3082
IMDG: UN 3082
IATA: UN 3082

14.2 UN proper shipping name
ADN: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b))
ADR: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b))
RID: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b))
IMDG: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Abamectin (combination of avermectin B1a and avermectin B1b))
IATA: Environmentally hazardous substance, liquid, n.o.s. (Abamectin (combination of avermectin B1a and avermectin B1b))
14.3 Transport hazard class(es)

<table>
<thead>
<tr>
<th>Class</th>
<th>ADN</th>
<th>ADR</th>
<th>RID</th>
<th>IMDG</th>
<th>IATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Value</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
<td>9</td>
</tr>
</tbody>
</table>

14.4 Packing group

**ADN**
- Packing group: III
- Classification Code: M6
- Hazard Identification Number: 90
- Labels: 9

**ADR**
- Packing group: III
- Classification Code: M6
- Hazard Identification Number: 90
- Labels: 9

**RID**
- Packing group: III
- Classification Code: M6
- Hazard Identification Number: 90
- Labels: 9

**IMDG**
- Packing group: III
- Labels: 9

**IATA (Cargo)**
- Packing instruction (cargo aircraft): 964
- Packing instruction (LQ): Y964
- Packing group: III
- Labels: Miscellaneous

**IATA (Passenger)**
- Packing instruction (passenger aircraft): 964
- Packing instruction (LQ): Y964
- Packing group: III
- Labels: Miscellaneous

14.5 Environmental hazards

**ADN**
- Environmentally hazardous: yes

**ADR**
- Environmentally hazardous: yes
RID
Environmentally hazardous : yes

IMDG
Marine pollutant : yes

IATA (Passenger)
Environmentally hazardous : yes

IATA (Cargo)
Environmentally hazardous : yes

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59) : Not applicable
REACH - List of substances subject to authorisation (Annex XIV) : Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable
Regulation (EC) No 850/2004 on persistent organic pollutants : Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:
Number on list 3


<table>
<thead>
<tr>
<th>E1</th>
<th>ENVIRONMENTAL HAZARDS</th>
<th>Quantity 1</th>
<th>Quantity 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>100 t</td>
<td>200 t</td>
</tr>
</tbody>
</table>

Other regulations:
Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Abamectin Liquid Formulation

IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H300 : Fatal if swallowed.
H311 : Toxic in contact with skin.
H330 : Fatal if inhaled.
H361fd : Suspected of damaging fertility. Suspected of damaging the unborn child.
H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.
H400 : Very toxic to aquatic life.
H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
Repr : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumu-
Further information

Sources of key data used to compile the Safety Data Sheet:

Classification of the mixture:
- Acute Tox. 4: H332 (Calculation method)
- STOT RE 2: H373 (Calculation method)
- Aquatic Acute 1: H400 (Calculation method)
- Aquatic Chronic 1: H410 (Calculation method)

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.